The Trust Layer for Market Analysts

The analysis discusses Oscar Health's performance, noting a 22% increase year-to-date and a recent earnings release. While revenue increased to $2.863 billion in the three months ending June 30, 2025, medical costs also jumped significantly to $2.552 billion. Membership grew by 33%, reaching just over 2 million. Management anticipates market stabilization and profitability by 2026. The discounted cash flow valuation model indicates an intrinsic value of $36.37 per share, down from a previous $40. Despite increased costs and decreased profitability, the analyst maintains a buy rating due to the expectation of normalized costs next year. The target is $36.37.